D2	Retention in care after early enrolment into differentiated service delivery models for antiretroviral treatment: a case for policy change	E-poster	Impact evaluation of differentiated service delivery
A21	Defining CTL immunotherapy candidates against replication-competent and defective HIV	On-demand oral abstract session	Immunotherapy: Vaccines and antibodies
A21	The balance of mucosal CD4 T cells prior to infection is associated with control of virus replication after therapeutic vaccination in SIV-infected rhesus macaques	On-demand oral abstract session	Immunotherapy: Vaccines and antibodies
A22	STAT modulation as strategy to improve NK cell cytotoxicity against HIV and cancer	On-demand oral abstract session	Immunotherapy: Immune-Modifying Agents
A22	Dual IL-10 and PD-1 blockade in SIVmac239 infected macaques promotes sustained virologic control in absence of ART	Oral abstract session with live Q&A	Immunotherapy: Immune-Modifying Agents
B45	New generation of HYBRID CAR-T cells efficiently kill HIV infected cells and neutralize cell-free virus	On-demand oral abstract session	Immune-based therapy trials
A30	Dysregulation of IFN-Î³, TNF-a, IL-12 and IL-18 secretion in newly diagnosed individuals with HIV/TB co-infection	E-poster	Immune responses during acute HIV infection
B80	Robust SARS-CoV-2-specific serological and functional t-cell immunity in PLWHIV	On-demand oral abstract session	Immune responses against SARS-CoV2 in PLWHIV
B27	HIV immune reconstitution inflammatory response syndrome and the risk of adverse pregnancy-fetal outcomes among ART naïve women aged 20-49 years in selected public hospitals, Nairobi, Kenya	On-demand oral abstract session	Immune reconstitution disorders and immune reconstitution inflammatory syndrome
A6	Plasma IL-21 associates with HIV-1 Neutralising potency of polyclonal IgG in the periphery	On-demand oral abstract session	Humoral immunity (including broadly neutralizing antibodies)